Signalling, inflammation and arthritis: NF-κB and its relevance to arthritis and inflammation

Rheumatology

Volumn 47, Issue 5, 2008, Pages 584-590

  Simmonds, R E ^a   Foxwell, B M ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

NF B; Review; Signalling pathways

Indexed keywords

CHEMOKINE; HETERODIMER; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; I KAPPA B KINASE EPSILON; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE; PROTEIN P50; SYNAPTOTAGMIN I; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL IMMORTALIZATION; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DRUG TARGETING; FIBROBLAST; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; KNOCKOUT MOUSE; LONG TERM CARE; MACROPHAGE; NONHUMAN; PANNUS; PHENOTYPIC VARIATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIOCYTE; TRANSACTIVATION;

ANIMALS; ARTHRITIS, RHEUMATOID; CELL LINE; HUMANS; I-KAPPA B KINASE; INFLAMMATION MEDIATORS; MICE; MODELS, ANIMAL; NF-KAPPA B; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 42949171833     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem298     Document Type: Article

References (92)

1. Kucharczak J, Simmons MJ, Fan Y, Gelinas C. To be, or not to be: NF-kappaB is the answer-role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 2003;22:8961-82.
2. Yousset S, Steinman L. At once harmful and beneficial: The dual properties of NF-kappaB. Nat Immunol 2006;7:901-2.
3. Chen LF, Greene WC. Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol 2004;5:392-401.
4. May MJ, Ghosh S. Signal transduction through NF-kappa B. Immunol Today 1998;19:80-8.
5. Li, Lu Q, Bottero V et al. Enhanced NF-kappaB activation and cellular function in macrophages lackng IkappaB kinase 1 (IKK1). Proc Nat Acad Sci USA 2005;102:12425-30.
6. Ciesielski CJ, Andreakos E, Foxwell BM, Feldmann M. TNFalpha-induced macrophage chemokine secretion is more dependent on NF-kappaB expression than lipopolysaccharides-induced macrophage chemokine secretion. Eur J Immunol 2002;32:2037-45.
7. Muller-Ladner U, Pap T, Gay RE, Neidhart M, Gay S. Mechanisms of disease: The molecular and cellular basis of joint destruction in rheumatoid arthritis. Nat Clin Pract Rheumatol 2005;1:102-10.
8. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001;19:163-96.
9. Fujisawa K, Aono H, Hasunuma T, Yamamoto K, Mita S, Nishioka K. Activation of transcription factor NF-kappa B in human synovial cells in response to tumor necrosis factor alpha. Arthritis Rheum 1996;39:197-203.
10. Roshak AK, Jackson JR, McGough K, Chabot-Fletcher M, Mochan E, Marshall LA. Manipulation of distinct NFkappaB proteins alters interleukin-1beta-induced human rheumatoid synovial fibroblast prostaglandin E2 formation. J Biol Chem 1996;271:31496-501.
11. Yamasaki S, Kawakami A, Nakashima T et al. Importance of NF-kappaB in rheumatoid synovial tissues: In situ NF-kappaB expression and in vitro study using cultured synovial cells. Ann Rheum Dis 2001;60:678-84.
12. Carlsen H, Moskaug JO, Fromm SH, Blomhoff R. In vivo imaging of NF-κB activity. J Immunol 2002;168:1441-6.
13. Sioud M, Mellbye O, Forre O. Analysis of the NF-kappa B p65 subunit, Fas antigen, Fas ligand and Bcl-2-related proteins in the synovium of RA and polyarticular JRA. Clin Exp Rheumatol 1998;16:125-34.
14. Marok R, Winyard PG, Coumbe A et al. Activation of the transcription factor nuclear factor-kappaB in human inflamed synovial tissue. Arthritis Rheum 1996;39:583-91.
15. Handel ML, McMorrow LB, Gravallese EM. Nuclear factor-kappa B in rheumatoid synovium. Localization of p50 and p65. Arthritis Rheum 1995;38:1762-70.
16. Benito MJ, Murphy E, Murphy EP, van den Berg WB, FitzGerald O, Bresnihan B. Increased syncMal tissue NF-kappa B1 expression at sites adjacent to the cartilage-pannus junction in rheumatoid arthritis. Arthritis Rheum 2004;50:1781-7.
17. Danning CL, Illei GG, Hitchon C, Greer MR, Boumpas DT, McInnes JB. Macrophage-derived cytokine, and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum 2000;43:1244-56.
18. Tsao PW, Suzuki T, Totsuka R et al. The effect of dexamethasone on the expression of activated NF-kappa B in adjuvant arthritis. Clin Immunol. Immunopathol 1997;83:173-8.
19. Han Z, Boyle DL, Manning AM, Firestein GS, AP-1 and NF-kappaB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 1998;28:197-208.
20. Campbell IK, Gerondakis S, O'Donnell K, Wicks IP. Distinct roles for the NF-kappaB1 (p50) and c-Rel transcription factors in inflammatory arthritis. J Clin Invest 2000;105:1799-806.
21. Lawrence T, Bebien M, Liu GY, Nizet V, Karin M. IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature 2005,434:1138-43.
22. Yamaoka S, Courtois G, Bessie C et al. Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation. Cell 1998;93:1231-40.
23. Rothwarf DM, Zandi E, Natoli G, Karin M. IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. Nature 1998;395:297-300.
24. Covert MW, Leung TH, Gaston JE, Baltimore D. Achieving stability of lipopolysaccharide-induced NF-kappaB activation. Science 2005;309:1854-7.
25. Kearns JD, Basak S, Werner SL, Huang CS, Hoffmann A. IkappaBepsilon provides negative feedback to control NF-kpppaB oscillations, signaling dynamics, and inflammatory gene expression, J Cell Biol 2006;173:659-64.
26. Doyle SL, O'Neill LA. Toll-like receptors: From the discovery of NFkappaB to new insights into transcriptional regulations in innate immunity. Biochem Pharmacol 2006;72:1102-13.
27. Udalova IA, Richardson A, Denys A et al. Functional, consequences of a polymorphism affecting NF-kappaB p50-p50 binding to the TNF promoter region. Mol Cell Biol 2000;20:9113-9.
28. Udalova IA, Richardson A, Ackerman H, Wordsworth P, Kwiatkowski D. Association of accelerated erosive rheumatoid arthritis with a polymorphism that alters NF-kappaB binding to the TNF promoter region. Rheumatology 2002;41:830-1.
29. Vanden Berghe W, Ndlovu MN, Hoya-Arlas R, Dijsselbloem N, Gerlo S, Haegeman G. Keeping up NF-kappaB appearances: Epigenetic control of immunity or inflammation-triggered epigenetics. Biochem Pharmacol 2006;72:1114-31.
30. Gerondakis S, Grossmann M, Nakamura Y, Pohl T, Grumont R. Genetic approaches in mice to understand Rel/NF-kappaB and IkappaB function: transgenics and knockouts. Oncogene 1999;18:6888-95.
31. Gerondakis S, Grumont R, Gugasyan R et al. Unravelling the complexities of the NF-kappaB signalling pathway using mouse knockout and transgenic models. Oncogene 2006;25:6781-99.
32. Pasparakis M, Luedde T, Schmidt-Supprian M. Dissection of the NF-kappaB signalling cascade in transgenic and knockout mice. Cell Death Differ 2006;13:861-72.
33. Cheng JD, Ryseck RP, Attar RM, Dambach D, Bravo R. Functional redundancy of the nuclear factor kappa B inhibitors I kappa B alpha and I kappa B beta. J Exp Med 1998;188:1055-62.
34. Mizgerd JP, Scott ML, Spieker MR, Doerschuk CM. Functions of IkappaB proteins in inflammatory responses to Escherichia coli LPS in mouse lungs. Am J Respir Cell Mol Biol 2002;27:575-82.
35. Alcamo E, Mizgerd JP, Horwitz BH et al. Targeted mutation of TNF receptor I rescues the RelA-deficient mouse and reveals a critical role for NF-kappa B in leukocyte recruitment. J Immunol 2001;167:1592-600.
36. Kim S, La Motte-Mohs RN, Rudolph D, Zuniga-Pflucker JC, Mak TW. The role of nuclear factor-kappaB essential modulator (NEMO) in B cell development and survival. Proc Natl Acad Sci USA 2003;100:1203-8.
37. Li Q, Van Antwerp D, Mercurio F, Lee KF, Verma IM. Severe liver degeneration in mice lacking the IkappaB kinase-2 gene. Science 1999;284:321-5.
38. Stratis A, Pasparakis M, Rupec RA et al. Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation, J Clin Invest 2006;116:2094-104.
39. Pasparakis M, Courtois G, Hafner M et al. TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature 2002;417:861-6.
40. Zaph C, Troy AE, Taylor BC et al. Epithelial-cell-intrinsic IKK-beta expression regulates intestinal immune homeostasis. Nature 2007;446:552-6.
41. Nenci A, Becker C, Wullaert A et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 2007;446:557-61.
42. Andreakos E, Smith C, Kiriakidis S et al. Heterogeneous requirement of IkappaB kinase 2 for inflammatory cytokine and matrix metalloproteinase production in rheumatoid arthritis: Implications for therapy. Arthritis Rheum 2003;48:1901-12.
43. Bondeson J, Browne KA, Brennan FM, Foxwell BM, Feldmann M. Selective regulation of cytokine induction by adenoviral gene transfer of IkappaBalpha into human macrophages: Lipopolysaccharide-induced, but not zymosan-induced, proinflammatory cytokines are inhibited, but IL-10 is nuclear factor-kappaB independent. J Immunol 1999;162:2939-45.
44. Xiao G, Rabson AB, Young W, Qing G, Qu Z. Alternative pathways of NF-kappaB activation: A double-edged sword in health and disease. Cytokine Growth Factor Rev 2006;17:281-93.
45. Basak S, Kim H, Kearns JD et al. A fourth IkappaB protein within the NF-kappaB signaling module. Cell 2007;128:369-81.
46. Smith C, Andreakos E, Crawley JB, Brennan FM, Feldmann M, Foxwell BM. NF-kappaB-inducing kinase is dispensable for activation of NF-kappaB in inflammatory settings but essential for lymphotoxin beta receptor activation of NF-kappaB in primary human fibroblasts. J Immunol 2001;167:5895-903.
47. Bours V, Franzoso G, Azarenko V et al. The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers. Cell 1993;72:729-39.
48. Motoyama M, Yamazaki S, Eto-Kimura A, Takeshige K, Muta T. Positive and negative regulation of nuclear factor-kappaB-mediated transcription by IkappaB-zeta, an inducible nuclear protein. J Biol Chem 2005;280:7444-51.
49. Yamazaki S, Muta T, Matsuo S, Takeshige K. Stimulus-specific induction of a novel nuclear factor-kappaB regulator, IkappaB-zeta, via Toll/ Interleukin-1 receptor is mediated by mRNA stabilization. J Biol Chem 2005;280:1678-87.
50. Hirotani T, Lee PY, Kuwata H et al. The nuclear IkappaB protein IkappaBNS selectively inhibits lipopolysaccharide-induced IL-6 production in macrophages of the colonic lamina propria. J Immunol 2005;174:3650-7.
51. Kuwata H, Matsumoto M, Atarashi K et al. IkappaBNS inhibits induction of a subset of Toll-like receptor-dependent genes and limits inflammation. Immunity 2006;24:41-51.
52. Wessells J, Baer M, Young HA et al. BCL-3 and NF-kappaB p50 attenuate lipopolysaccharide-induced inflammatory responses in macrophages. J Biol Chem 2004;279:49995-50003.
53. Kuwata H, Watanabe Y, Miyoshi H et al. IL-10-inducible Bcl-3 negatively regulates LPS-induced TNF-alpha production in macrophages. Blood 2003;102:4123-9.
54. Nolan GP, Fujita T, Bhatia K et al. The bcl-3 proto-oncogene encodes a nuclear I kappa B-like molecule that preferentially interacts with NF-kappa B p50 and p52 in a phosphorylation-dependent manner. Mol Cell Biol 1993;13:3557-66.
55. Franzoso G, Bours V, Azarenko V et al. The oncoprotein Bcl-3 can facilitate NF-kappa B-mediated transactivation by removing inhibiting p50 homodimers from select kappa B sites. EMBO J 1993;12:3893-901.
56. Zhang Q, Didonato JA, Karin M, McKeithan TW. BCL3 encodes a nuclear protein which can alter the subcellular location of NF-kappa B proteins. Mol Cell Biol 1994;14:3915-26.
57. Yamamoto M, Yamazaki S, Uematsu S et al. Regulation of Toll/ IL-1-receptor-mediated gene expression by the inducible nuclear protein IkappaBzeta. Nature 2004;430:218-22.
58. Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 2007;8:49-62.
59. Pandey S, Agrawal DK. Immunobiology of toll-like receptors: Emerging trends. Immunol Cell Biol 2006;84:333-41.
60. Andreakos E, Sacre SM, Smith C et al. Distinct pathways of LPS-induced NF-kappa B activation and cytokine production in human myeloid and nonmyeloid cells defined by selective utilization of MyD88 and Mal/TIRAP. Blood 2004;103:2229-37.
61. Sacre SM, Lundberg AM, Andreakos E, Taylor C, Feldmann M, Foxwell BM. Selective use of TRAM in lipopolysaccharide (LPS) and lipoteichoic acid (LTA) induced NF-kappaB activation and cytokine production in primary human cells: TRAM is an adaptor for LPS and LTA signaling, J Immunol 2007;178:2148-54.
62. van der Heijden IM, Wilbrink B, Tchetverikov I et al. Presence of bacterial DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and other arthritides. Arthritis Rheum 2000;43:593-8.
63. Yu M, Wang H, Ding A et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 2006;26:174-9.
64. Sato H, Miyata M, Kasukawa R. Expression of heat shock protein on lymphocytes in peripheral blood and synovial fluid from patients with rheumatoid arthritis. J Rheumatol 1996;23:2027-32.
65. Ohashi K, Burkart V, Flohe S, Kolb H. Cutting edge: Heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 2000;164:550-61.
66. Roelofs MF, Boolens WC, Joosten LA et al. Ideniffication of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of rheumatoid arthritis. J Immunol 2006; 176:7021-7.
67. Okamura Y, Watari M, Jerud ES et al. The extra domain A of fibronectin activates toll-like receptor 4. J Biol Chem 2001;276:10229-33.
68. Termeer C, Benedix F, Sleeman J et al. Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 2002;195:99-111.
69. Seibl R, Birchler T, Loeliger S et al. Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium. Am J Pathol 2003;162:1221-7.
70. Iwahashi M, Yamamura M, Aita T et al. Expression of toll-like receptor 2 on CD16+ blood monocytes and synovial tissue macrophages in rheumatoid arthritis. Arthritis Rheum 2004;50:1457-67.
71. Radstake TR, Roelofs MF, Jenniskens YM et al. Expression of toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-gamma. Arthritis Rheum 2004; 50:3856-65.
72. Brentano F, Schorr O, Gay RE, Gay S, Kyburz D. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via toll-like receptor 3. Arthritis Rheum 2005;52:2656-65.
73. Roelofs MF, Joosten LA, Abdollahi-Roodsaz S et al. The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum 2005;52:2313-22.
74. Brennan FM, Hayes AL, Ciesielski CJ, Green P, Foxwell BM, Feldmann M. Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: Involvement of phosphatidylinositol 3-kinase and nuclear factor kappaB pathways in tumor necrosis factor alpha production in rheumatoid arthritis. Arthritis Rheum 2002;46:31-41.
75. Beech JT, Andreakos E, Ciesielski CJ, Green P, Foxwell BM, Brennan FM. T-cell contact-dependent regulation of CC and CXC chemokine production in monocytes through differential involvement of NFkappaB: Implications for rheumatoid arthritis. Arthritis Res Ther 2006;8:R168.
76. Lundberg AM, Drexler SK, Monaco C et al. Key differences in TLR3/ poly I:C signaling and cytokine induction by human pAimary cells: a phenomenon absent from murine cell systems. Blood 2007;110:3245-52.
77. Sharif O, Bolshakov VN, Raines S, Newham P, Perkins ND. Transcriptional profiling of the LPS induced NF-kappaB response in macrophages. BMC Immunol 2007;8:1.
78. Malinin NL, Boldin MP, Kovalenko AV, Wallach D. MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature 1997;385:540-4.
79. Shinkura R, Kitada K, Matsuda F et al. Alymphoplasia is caused by a point mutation in the mouse gene encoding Nf-kappa b-inducing kinase. Nat Genet 1999;22:74-7.
80. Yin L, Wu L, Wesche H et al. Defective lymphotaxin-beta receptor-induced NF-kappaB transcriptional activity in NIK-deficient mice. Science 2001;291;2162-5.
81. Sacre SM, Andreakos E, Taylor P, Feldmann M, Foxwell BM. Molecular therapeutic targets in rheumatoid arthritis. Expert Rev Mol Med 2005;7:1-20.
82. Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: A treasure trove for drug development. Nat Rev Drug Discov 2004;3:17-26.
83. Drexler S, Turner JJO, Foxwell BM. Clinical prospects of NF-kappaB inhibitors. In: Smolen JS, Lipsky P, eds. Further Targeted Therapies in Rheumatology. London: Martin Dunitz, 2007. In press.
84. Christopher JA, Avitabile BG, Bamborough P et al. The discovery of 2-amino-3,5- diarylbenzamide inhibitors of IKK-alpha and IKK-beta kinases. Bioorg Med Chem Lett 2007; 17:3972-7.
85. Belema M, Bunker A, Nguyen VN et al. Synthesis and structure-activity relationship of imidazo(1,2-a)thieno(3,2-e)pyrazines as IKK-beta inhibitors. Bioorg Med Chem Lett 2007;17:4284-9.
86. Bonafoux D, Bonar S, Christine L et al. Inhibition of IKK-2 by 2-[(aminocarbonyl) amino]-5-acetylenyl-3-thiophenecarboxamides. Bioorg Med Chem Lett 2009;15:2870-5.
87. Podolin PL, Callahan JF, Bolognese BJ et al. Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl) amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell proliferation. J Pharmacol Exp Ther 2005;312:373-81.
88. McIntyre KW, Shuster DJ, Gillooly KM et al. A highly selective inhibitor of I kappa B kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice. Arthritis Rheum 2003;48:2652-9.
89. Izmailova ES, Paz N, Alencar H et al. Use of molecular imaging to quantify response to IKK-2 inhibitor treatment in murine arthritis. Arthritis Rheum 2007;56:117-28.
90. Godl K, Wissing J, Kurtenbach A et al. An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc Natl Acad Sci USA 2003;100:15434-9.
91. Tas SW, Adriaansen J, Hajji N & et al. Amelioration of arthritis by intraarticular dominant negative Ikk beta gene therapy using adeno-associated virus type 5. Hum Gene Ther 2006;17:821-32.
92. Yamazaki S, Muta T, Takeshige K. A novel IkappaB protein, IkappaB-zeta, induced by proinflammatory stimuli negatively regulates nuclear factor-kappaB in the nuclei. J Biol Chem 2001;276:27657-62.